In This Section

Program

Please note that this meeting will take place as an in-person event in Boston and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference. Please see the registration page for details.

CME credit is available for in-person attendance for the designated sessions. On-demand presentations are not eligible for CME.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Friday, october 18

saturday, october 19

sunday, october 20

monday, october 21

Friday, October 18

Welcome and Opening Keynote

6:30-7:30 p.m. | CME Eligible

  • 6:30 p.m. | Welcome and Introduction of Keynote Speaker
    Yvonne Y. Chen, University of California, Los Angeles, California
  • 6:35 p.m. | Keynote Lecture
    Susan M. Kaech, Salk Institute for Biological Studies, La Jolla, California
  • 7:15 p.m. | Discussion / Q&A

OPENING RECEPTION

7:30-9:30 p.m.

Saturday, October 19

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 1: Good and Bad CD4 T cell Help

8-10:05 a.m. | CME Eligible

Session Chair: Sergio Quezada, University College London (UCL) Cancer Institute, London, England

  • 8:05 a.m. | Cancer biomarker defining the subset of HPV16+ head and neck cancer patients benefiting from therapeutic vaccine combination with anti-PD-1
    Cornelis JM Melief, ISA Pharmaceuticals, Oegstgeest, Netherlands
  • 8:35 a.m. | Treg targeting at the interface of adaptive and innate immunity-targetable bad help
    Sergio Quezada
  • 9:05 a.m. | Title to be announced
    Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri

Short talks selected from proffered abstracts

BREAK

10:05-10:25 a.m.

Plenary Session 2: Mass Spectrometry / MHC

10:25-12:30 p.m. | CME Eligible

Session Chair: To be announced

  • 10:30 a.m. |Using FAIMS to improve detection of tumor neoantigens
    Cheryl Lichti, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 11 a.m. | Insight into PTM-driven antigenicity
    Yifat Merbl, Wiezmann Institute of Science, Rehovat, Israel
  • 11:30 a.m. | Immunopeptidomic-driven exploration of the tumor antigenic landscape
    Michal Bassani Sternberg, University of Lausanne, Lausanne, Switzerland

Short talks selected from proffered abstracts

Lunch on own

12:30-2:30 p.m.

Plenary Session 3: T-cell Engineering / Cellular Therapy

2:30-4:35 p.m. | CME Eligible

Session Chair: Yvonne Y. Chen, University of California, Los Angeles, California

  • 2:30 p.m. | Engineering multi-pronged CAR-T cell therapy for solid tumors
    Yvonne Y. Chen
  • 3:05 p.m. | Title to be announced
    Robbie G. Majzner, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 3:35 p.m. | Fourth generation CAR-Tregs
    Megan Levings, BC Children’s Hospital Research Institute, Vancouver, BC, Canada

Short talks selected from proffered abstracts

Cancer Immunology (CIMM) Working Group Session: Novel Approaches in Antigen Target Discovery

4:45-5:45 p.m. | CME Eligible

Session Chair: Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts

  • 4:45 p.m. | Genomic and immunoproteomic approaches for neoantigen discovery
    Catherine J. Wu
  • 5 p.m. | Systematic approaches for tumor antigen discovery using high throughput serologic screening
    Aaron Ring, Fred Hutchinson Cancer Center, Seattle, Washington
  • 5:15 p.m. | Systemic approaches to discover targets to tumor-reactive T cells
    Wouter Scheper, Netherlands Cancer Institute, Amsterdam, Netherlands
  • 5:30 p.m. | Panel Discussion

Poster Session A/reception

6-8:15 p.m.

Sunday, October 20

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 4: New Checkpoints and Combinations

8-10:05 a.m. | CME Eligible

Session Chair: Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC

  • 8 a.m. | Distinct immune checkpoint gene signatures of breast cancer subtypes with and without HER2-regulated stromal cell genes
    Fernando Vidal-Vanaclocha
  • 8:10 a.m. | Title to be announced
    Marco Colonna, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 8:40 a.m. | Title to be announced
    Roberta Zappasodi, Weill Cornell Medicine, New York, New York
  • 9:10 a.m. | Title to be announced
    Pablo Umana, Roche, Schlieren, Switzerland

Short talks selected from proffered abstracts

BREAK

10:05-10:25 a.m.

Plenary Session 5: Vaccines

10:25 a.m.-12:15 p.m. | CME Eligible

Session Chair: Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri

In honor of Dr. Jeffrey S. Weber

  • 10:30-11 a.m. | Title to be announced
    Catherine J. Wu, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 11-11:30 a.m.| Personalized RNA vaccines for pancreatic cancer
    Vinod P. Balachandran, Memorial Sloan Kettering Cancer Center, New York, New York
  • 11:30 a.m. -12 p.m. | Short Talks
  • 12-12:15 p.m. | Panel Discussion

Short talks selected from proffered abstracts

LUNCH BREAK (ON YOUR OWN) 

12:15-2:30 p.m.

Plenary Session 6: Emerging Technologies, Microbiome, and Immunometabolism

2:30-4:35 p.m | CME Eligible

Session Chair: To be announced

  • 2:35 p.m. | Title to be announced
    Thomas F. Gajewski, University of Chicago, Chicago, Illinois
  • 3:05 p.m. | Title to be announced
    Giorgio Trinchieri, National Cancer Institute, Bethesda, Maryland
  • 3:35 p.m. | Leveraging metabolic reprogramming to improve cellular therapies for cancer
    Greg M. Delgoffe, University of Pittsburgh, Pittsburgh, Pennsylvania

Short talks selected from proffered abstracts

break

4:35-4:50 p.m.

Keynote Lecture

4:50-5:50 p.m. | CME Eligible

  • 4:50 p.m. | Introduction of Keynote Speaker
    Robert D. Schreiber, Washington University School of Medicine in St. Louis, St. Louis, Missouri
  • 4:55 p.m. | Large-scale mapping of TCR-pMHC interactions
    Ton Schumacher, Netherlands Cancer Institute, Amsterdam, Netherlands
  • 5:35 p.m. | Discussion / Q&A

Poster Session B/reception

6-8:15 p.m.

Monday, October 21

CONTINENTAL BREAKFAST

7-8 a.m.

Plenary Session 7: Myeloid and NK Cells

8-9:50 a.m. | CME Eligible

Session Chair: To be announced

  • 8:05 a.m. | Retroviral mimics costimulate TLR7/8/9 for enhanced activation of dendritic cells and myeloid cells to induce anti-tumor CD8+ T cells
    Arthur M. Krieg, University of Massachusetts Chan Medical School, Needham, Massachusetts
  • 8:35 a.m. | Title to be announced
    Matthew Spitzer, University of California, San Francisco, California

Short talks selected from proffered abstracts

BREAK

9:50-10:05 a.m.

Plenary Session 8: Clinical and Biological Intersection

10:05 a.m.-12:15 p.m. | CME Eligible

Session Chair: Fernando Vidal-Vanaclocha, The George Washington University, Washington, DC

  • 10:10 a.m. | Title to be announced
    Elizabeth M. Jaffee, Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland
  • 10:40 a.m. | Integrating clinical and laboratory research to identify mechanisms of response and resistance to immune checkpoint therapy
    Padmanee Sharma, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 11:10 a.m. | Diffuse large B-cell lymphoma and neurotoxicity following CAR-T cell immunotherapy: Contributing factors and Blood-brain barrier impairment biomarkers
    Fernando Vidal-Vanaclocha

Short talks selected from proffered abstracts

Closing Remarks/departure

12:15 p.m.